755 results on '"Massard, C."'
Search Results
2. A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors
3. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
4. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
5. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
6. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
7. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
8. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
9. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
10. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
11. Photoactive TiO2 antibacterial coating on surgical external fixation pins for clinical application
12. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
13. Photopolymerizable hybrid sol gel coating as a barrier against plasticizer release
14. Entitäten-unabhängige Sicherheit und Wirksamkeit von Erdafitinib bei Patienten mit fortgeschrittenen soliden Tumoren mit präspezifizierten genomischen FGFR- Aberrationen (RAGNAR Interimanalyse)
15. Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
16. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
17. Who dies from prostate cancer?
18. Enzalutamide and sleep apnea: an emerging central nervous system side-effect?
19. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
20. How to select targeted therapy in renal cell cancer
21. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
22. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
23. Incidence of brain metastases in renal cell carcinoma treated with sorafenib
24. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
25. Why do residents choose the medical oncology specialty? Implications for future recruitment—results of the 2007 French Association of Residents in Oncology (AERIO) Survey
26. Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
27. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
28. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
29. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
30. Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
31. 2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
32. 230P Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
33. 192P Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
34. 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
35. 516P Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
36. The postchemotherapy PSA surge syndrome
37. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
38. Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients
39. Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
40. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
41. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma
42. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
43. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors
44. Tumour stem cell-targeted treatment: elimination or differentiation
45. How to select amongst available options for the treatment of advanced RCC?
46. Novel and bone-targeted agents for CRPC
47. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
48. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases
49. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
50. Bevacizumab-induced laryngeal necrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.